Pharmacyclics Revenue and Competitors

Claim your profile

Location

$14.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Pharmacyclics's estimated annual revenue is currently $750M per year.(i)
  • Pharmacyclics's estimated revenue per employee is $794,492
  • Pharmacyclics's total funding is $14.5M.

Employee Data

  • Pharmacyclics has 944 Employees.(i)
  • Pharmacyclics grew their employee count by -2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Pharmacyclics is a pharmaceutical company developing novel agents to improve current therapeutic approaches to cancer, cardiovascular diseases, and inflammation. The company’s products are rationally designed, ring-shaped small molecules called texaphyrins. Texaphyrins selectively concentrate in diseased tissue, such as tumor cells and vulnerable plaque. They disrupt the bioenergetic processes of these cells, and when combined with other treatment modalities or various forms of energy, such as chemotherapy, radiation or light, apoptosis (programmed cell death) of the diseased tissue occurs. In this manner, texaphyrins can help to reduce or eliminate the diseased tissue

keywords:N/A

$14.5M

Total Funding

944

Number of Employees

$750M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pharmacyclics News

2022-04-19 - Imbruvica Market 2022 Enhancement, Growth Rate Analysis ...

AbbVie (Pharmacyclics), Johnson & Johnson (Janssen Biotech), SP Laboratories. The Global Imbruvica Market Report includes the top companies...

2022-04-17 - Rilzabrutinib active, safe in immune thrombocytopenia

“Prior research with ibrutinib [Imbruvica; Pharmacyclics, Janssen] had shown that patients with chronic lymphocytic leukemia and immune...

2014-11-04 - AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology

AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology 04-11-2014 Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological cancers AstraZeneca and Pharmacyclics, Inc. today ann ...

2014-11-04 - AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology

AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology 04-11-2014 Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological cancers AstraZeneca and Pharmacyclics, Inc. today ann ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$75M102023%N/A
#2
$209.1M1030N/AN/A
#3
$298.4M10415%$288.6M
#4
$453M1152-27%$89.3M
#5
$241.4M118914%N/A